Abstract
The high recurrence rate and the low overall survival in ovarian cancer suggest that a more specific therapeutic approach in addition to conventional treatment is required. Translational and clinical research is investigating new molecular targets in order to find an alternative way to affect tumor growth and to minimize the overlap of toxicity of antiblastic agents. Given its implication in many cellular activities including regulation of cell growth, motility, survival, proliferation, protein synthesis, autophagy, transcription, as well as angiogenesis, PI3K/AKT/mTOR is one of the most investigated intracellular signaling pathways. A dis-regulation of this pathway has been shown in several tumors, including ovarian cancer. In this setting, mTor proteins represent a potential target for inhibitors, which could ultimately play a pivotal role in counteracting cellular proliferation. Recently, mTor inhibitors have been approved in the treatment of pancreatic neuroendocrine tumors, mantle cell lymphoma and renal cancer. Clinical trials have assessed the safety of these drugs in ovarian cancer patients. Ongoing phase I and II studies are evaluating the oncologic outcome of mTor inhibitor treatment and its effect in combination with...Continue Reading
Citations
Jul 31, 2019·Analytical Cellular Pathology (Amsterdam)·Attalla Farag El-KottSultan Alqahtani
Sep 25, 2019·Cancers·Periklis KatopodisEmmanouil Karteris
May 21, 2020·Cancers·Panagiotis DalezisDimitrios T Trafalis
Aug 30, 2020·Journal of Cellular and Molecular Medicine·Xiaoqing WangWeiling Li
Aug 16, 2018·Journal of Cancer Research and Clinical Oncology·Maria Luisa GasparriElisabetta Ferretti
Jul 10, 2019·Cancers·Alia Ghoneum, Neveen Said
Dec 4, 2019·International Journal of Oncology·Mingxi XuZhong Wang
Nov 13, 2019·Medical Oncology·Carlos Eduardo Perez-JuarezLaura Diaz-Cueto
Mar 20, 2020·Open Medicine·Yan DingYoujun Cao
Mar 15, 2019·Experimental and Therapeutic Medicine·Yiyun Tan, Lei Liu
Jul 2, 2020·Cancers·Xuewei ZhangNobuo Yaegashi
Mar 19, 2020·Marine Drugs·Hyocheol BaeWhasun Lim
Mar 14, 2020·Clinical Proteomics·Allison L HuntThomas P Conrads
Mar 17, 2020·Frontiers in Oncology·Tracess SmalleyMildred Acevedo-Duncan
Jan 27, 2019·Archives of Pharmacal Research·Garam KimHong Seok Choi
Feb 19, 2020·BMC Complementary Medicine and Therapies·Li HanHua Bian
Aug 28, 2020·The EPMA Journal·Marek SamecPeter Kubatka
Oct 13, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Yanting ZhuDaohua Shi
Sep 25, 2019·The International Journal of Biochemistry & Cell Biology·Lingling GaoBei Lin
Oct 23, 2020·Pharmacology & Therapeutics·Martina ChiacchiariniElisabetta Ferretti
Apr 3, 2021·Cancer Cell International·Zeeshan JavedJavad Sharifi-Rad
Sep 25, 2020·Asia-Pacific Journal of Clinical Oncology·Rana Muhammad UsmanFaiz Anwer
Nov 26, 2020·Aging·Jiang RuibinGu Linhui
May 10, 2020·Cellular Oncology (Dordrecht)·Yangjiong XiaoRong Zhang
Apr 2, 2021·Biochemical Pharmacology·Jing ZhaoShuhua Zhao
Jun 25, 2021·Journal of Ovarian Research·Huixi WengZhiqun Zheng
Jul 20, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry· IksenVarisa Pongrakhananon
Aug 7, 2021·Biomolecules·Chao-Lien LiuTsui-Lien Mao
Aug 28, 2021·Biomedicines·Santosh Kumar SinghRajesh Singh
Oct 25, 2021·Cancer Science·Hoshino DaisukeNaohiko Koshikawa